Article
Oncology
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, Shigeki Yoshiura, Naoki Harada, Yasushi Yoshimura
Summary: Retreatment with obinutuzumab in combination with chemotherapeutic agents is effective in CD20-positive obinutuzumab-induced direct-cell-death-resistant cells, showing significant antitumor effects in mouse xenograft models.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Hematology
Andrew J. Doyle, Matthew J. Stubbs, Will Lester, Will Thomas, John-Paul Westwood, Mari Thomas, Charles Percy, Nithya Prasannan, Marie Scully
Summary: Obinutuzumab and ofatumumab may be considered as alternative options to rituximab in the treatment of iTTP, with a comparable safety profile, absence of significant hypersensitivity reactions, and sustained normalization of ADAMTS13.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Clinical Neurology
Corinna Quendt, Jasmin Ochs, Silke Haeusser-Kinzel, Darius Haeusler, Martin S. Weber
Summary: The frequency and effects of CD20(+) T cells in patients with multiple sclerosis vary depending on the treatment method, with some extinguishing the cells while others only reducing their abundance as part of a broader T cell suppressive capacity.
ANNALS OF NEUROLOGY
(2021)
Article
Neurosciences
Emanuele D'Amico, Aurora Zanghi, Roberta Fantozzi, Diego Centonze, Carlo Avolio
Summary: The study aimed to investigate the changes in cellular subsets of patients with relapsing Multiple Sclerosis (RMS) before and after treatment with Ofatumumab. The results showed an increase in CD3+ T cell frequencies and a significant decrease in B naive cells after 4 and 12 weeks of treatment.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Immunology
Julia Baguna Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Summary: This study investigated the distribution and efficacy of ofatumumab and ocrelizumab in huCD20 transgenic mice, revealing differences in tissue distribution patterns between subcutaneous and intravenous administration, with the possibility of more direct access to lymph nodes through the lymphatic system with subcutaneous administration. Additionally, preliminary findings suggest that ofatumumab may be more effective than ocrelizumab at controlling MS-like pathology in the brain.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sabine Tacke, Rittika Chunder, Verena Schropp, Eduard Urich, Stefanie Kuerten
Summary: This study investigated the effects of a novel class of anti-CD20 monoclonal antibodies on B cells in an animal model of multiple sclerosis. The results showed that these antibodies can modulate the immune response and pathology of the central nervous system driven by B cells, with type II antibodies potentially being more effective in depleting tissue-infiltrating B cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
Alexandre Lemieux, Maud Maho-Vaillant, Marie-Laure Golinski, Vivien Hebert, Olivier Boyer, Sebastien Calbo, Sophie Candon, Pascal Joly
Summary: This study found that ARAs are frequently detected in pemphigus patients treated with RTX and are generally not associated with patient outcomes. Only patients with the combination of ARAs, low RTX concentration, incomplete B-cell depletion, and persistent serum anti-DSG3 Abs seem to be at high risk of relapse.
Article
Rheumatology
Venkat R. Reddy, Ruth J. Pepper, Kavina Shah, Geraldine Cambridge, Scott R. Henderson, Christian Klein, Loren Kell, Samuel J. Taylor, David A. Isenberg, Mark S. Cragg, Maria J. Leandro
Summary: This study investigated the factors contributing to the variability of rituximab-mediated B cell depletion (BCD) in systemic lupus erythematosus (SLE). The results showed that BCD was less efficient in SLE compared to rheumatoid arthritis (RA). B cells were detectable in renal biopsy samples of SLE patients who had a poor response to rituximab. No significant relationships were found between peripheral BCD and patient demographics or B cell surface protein expression. Obinutuzumab was more efficient than rituximab at inducing BCD.
Article
Dentistry, Oral Surgery & Medicine
Antonio Alexandre Coelho, Rute Romao Carvalho, Ana Luiza Muniz, Andre Alves Crispim, Anderson Maia Meneses, Carla Welch da Silva, Dayrine Silveira de Paula, Ana Paula Negreiros Nunes Alves, Fabricio Bitu Sousa, Paulo Goberlanio de Barros Silva
Summary: The study aimed to evaluate the role of CD20 + cells in the healing process of oral traumatic ulcers (OTU) in rats. The results showed that blocking CD20 + cells with anti-CD20 rituximab (RTX) reduced cell migration, acute inflammation, and wound healing in OTU.
ARCHIVES OF ORAL BIOLOGY
(2024)
Article
Oncology
Michael Constantinides, Alexis Fayd'herbe De Maudave, Marie Potier-Cartereau, Mauricio Campos-Mora, Guillaume Cartron, Martin Villalba
Summary: CD20 monoclonal antibodies have a strong ability to quickly kill B cells using different mechanisms. However, the assessment of killing is difficult. This study shows that common cytometry protocols involving centrifugation can miss important parts of the killing effect of drugs. Alternative methods are proposed to assess fast target cell killing in vitro, avoiding centrifugation or based on survival comparison or counting beads, which are applicable to B cell lines and primary tumor cells.
Article
Immunology
Xiangjuan Guo, Tongtong Ji, Shengliang Xin, Jinghang Xu, Yanyan Yu
Summary: A 72-year-old woman with isolated HBcAb positive developed HBV reactivation during R-CHOP therapy for diffuse large B-cell lymphoma. Reactivation was confirmed based on detectable HBV DNA until 19 months post-therapy, which became undetectable after TAF treatment. Regular monitoring is crucial for timely diagnosis and management of HBV reactivation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Clinical Neurology
Finn Sellebjerg, Martin S. Weber
Summary: Therapies targeting B cells in MS, including monoclonal antibodies, show promising efficacy in suppressing radiological disease activity and relapse. However, safety concerns such as increased risk of infections and blunted vaccine responses should be taken into account. Further research is needed to determine the optimal dosing regimens and potential advantages of novel approaches targeting CD19 or BTK compared to anti-CD20 therapy.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joe Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Summary: This study found that patients with previously untreated CLL who received Ven-Obi had significantly better PFS compared to those who received Clb-Obi, and the MRD status at the end of therapy was associated with PFS duration. The results reveal the sustained long-term efficacy of Ven-Obi in treating previously untreated CLL.
NATURE COMMUNICATIONS
(2023)
Article
Hematology
Zhiwei Ang, Luca Paruzzo, Katharina E. Hayer, Carolin Schmidt, Manuel Torres Diz, Feng Xu, Urvi Zankharia, Yunlin Zhang, Samantha Soldan, Sisi Zheng, Catherine D. Falkenstein, Joseph P. Loftus, Scarlett Y. Yang, Mukta Asnani, Patricia King Sainos, Vinodh Pillai, Emeline Chong, Marilyn M. Li, Sarah K. Tasian, Yoseph Barash, Paul M. Lieberman, Marco Ruella, Stephen J. Schuster, Andrei Thomas-Tikhonenko
Summary: Skipping of coding exons in CD19 and CD22 genes compromises immunotherapy response in B-cell malignancies. This study demonstrates that CD20 gene (MS4A1) also produces multiple mRNA isoforms with distinct untranslated regions. Modulating CD20 isoforms enhances CD20 expression and antibody-mediated cytotoxicity, potentially overcoming immunotherapy resistance.
Article
Rheumatology
Naomi A. Amudala, Sara Boukhlal, Brittany Sheridan, Carol A. Langford, Abdallah Geara, Peter A. Merkel, Divi Cornec
Summary: Obinutuzumab appears to be a safe and efficacious therapy for patients with ANCA-associated vasculitis who have had refractory disease or a history of anaphylaxis to rituximab. Prospective studies comparing rituximab to obinutuzumab in ANCA-associated vasculitis patients are warranted.
Article
Immunology
Kerstin Renner, Sophia Neumayer, Yvonne Talke, Simone Buchtler, Kathrin Schmidbauer, Falk Nimmerjahn, Anja Lux, Frederike Winter, Jan-Nicklas Salewski, Matthias Mack
Summary: B-cell modulation through targeting CD79b can achieve therapeutic effects in autoimmune diseases like MS, offering an alternative approach to complete B-cell depletion with anti-CD20 antibodies.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Article
Cell Biology
Mehmet Sahin, Melissa M. Remy, Benedict Fallet, Rami Sommerstein, Marianna Florova, Anna Langner, Katja Klausz, Tobias Straub, Mario Kreutzfeldt, Ingrid Wagner, Cinzia T. Schmidt, Pauline Malinge, Giovanni Magistrelli, Shozo Izui, Hanspeter Pircher, J. Sjef Verbeek, Doron Merkler, Matthias Peipp, Daniel D. Pinschewer
Summary: In this study, the role of antibody multivalency in protecting neutralizing and non-neutralizing antibodies in virus-infected mice was investigated. The results showed that antibody bivalency enables the tethering of virions to the infected cell surface and inhibits virion release, independently of Fc gamma receptor interactions. The protection in mice was found to be correlated with the virus-release-inhibiting activity of the antibodies rather than their neutralizing capacity. These findings provide insights into the evolutionary conservation of antibody multivalency and have implications for vaccine development targeting non-neutralizing antibodies.
Article
Hematology
Kristina Mueller, Fotini Vogiatzi, Dorothee Winterberg, Thies Rosner, Lennart Lenk, Lorenz Bastian, Carina L. Gehlert, Marie-Pauline Autenrieb, Monika Bruggemann, Gunnar Cario, Martin Schrappe, Andreas E. Kulozik, Cornelia Eckert, Anke K. Bergmann, Beat Bornhauser, Jean-Pierre Bourquin, Thomas Valerius, Matthias Peipp, Christian Kellner, Denis M. Schewe
Summary: This study suggests that combining CD47 blockade with Dara is a promising therapy for T-ALL, especially for relapsed/refractory disease harboring a dismal prognosis in patients.
Review
Immunology
Matthias Peipp, Katja Klausz, Ammelie Svea Boje, Tobias Zeller, Stefan Zielonka, Christian Kellner
Summary: NK cells play a crucial role in cancer immune surveillance by recognizing malignant cells and controlling their activation through the expression of activating and inhibitory receptors. The recruitment and activation of NK cells have great potential in cancer treatment. Targeting the ligands expressed on tumors is also a promising approach to unleash the cytotoxicity of NK cells.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Nicole Baeumer, Jessica Tiemann, Annika Scheller, Theresa Meyer, Lisa Wittmann, Matias Ezequiel Gutierrez Suburu, Lilo Greune, Matthias Peipp, Neele Kellmann, Annika Gumnior, Caroline Brand, Wolfgang Hartmann, Claudia Rossig, Carsten Muller-Tidow, Dario Neri, Cristian A. Strassert, Christian Rueter, Petra Dersch, Georg Lenz, H. Phillip Koeffler, Wolfgang E. Berdel, Sebastian Baeumer
Summary: A study found that the small arginine-rich protein protamine can condense genomic DNA into the sperm head, and its high RNA binding capacity can be utilized for the spontaneous electrostatic assembly of therapeutic nanoparticles decorated with tumor-cell-specific antibodies for efficient targeting of siRNA. These nanoparticles showed promising results in treating non-small-cell lung cancer and Ewing sarcoma models.
Article
Virology
Ulf Martin Geisen, Ruben Rose, Franziska Neumann, Maria Ciripoi, Lena Vullriede, Hayley M. Reid, Dennis Kristopher Berner, Federico Bertoglio, Paula Hoff, Michael Hust, Ann Carolin Longardt, Thomas Lorentz, Gabriela Rios Martini, Carina Saggau, Jan Henrik Schirmer, Maren Schubert, Melike Suembuel, Florian Tran, Mathias Voss, Rainald Zeuner, Peter J. Morrison, Petra Bacher, Helmut Fickenscher, Sascha Gerdes, Matthias Peipp, Stefan Schreiber, Andi Krumbholz, Bimba Franziska Hoyer
Summary: The humoral immune response declines more rapidly with TNF-alpha inhibition in patients with chronic inflammatory disease. The efficacy of current vaccines against Omicron variants, including BA.2, is limited. Alterations in immune cell populations, changes in IgG affinity, and the ability to neutralize the virus were investigated in these at-risk patients.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Immunology
Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, Sebastian Lutz, Nikos Darzentas, Henrik Knecht, Dietrich Herrmann, Monika Brueggemann, Axel J. Scheidig, Katja Weisel, Martin Gramatzki, Matthias Peipp, Katja Klausz
Summary: New antibodies with therapeutic potential for multiple myeloma (MM) immunotherapy can be identified using phage display and deep sequencing.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Cristian Papara, Christian M. Karsten, Hideyuki Ujiie, Enno Schmidt, Leon F. Schmidt-Jimenez, Adrian Baican, Patricia C. Freire, Kentaro Izumi, Katja Bieber, Matthias Peipp, Admar Verschoor, Ralf J. Ludwig, Joerg Koehl, Detlef Zillikens, Christoph M. Hammers
Summary: Pemphigoid diseases are chronic inflammatory skin diseases characterized by blistering and autoantibodies. Complement plays an important role in these diseases, but recent studies have shown that inflammation can occur independently of complement.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Niklas Baumann, Christian Arndt, Judith Petersen, Marta Lustig, Thies Roesner, Katja Klausz, Christian Kellner, Miriam Bultmann, Lorenz Bastian, Fotini Vogiatzi, Jeanette H. W. Leusen, Renate Burger, Denis M. Schewe, Matthias Peipp, Thomas Valerius
Summary: Antibody-based immunotherapy is increasingly used to treat acute lymphoblastic leukemia (ALL) patients. This study investigates the effects of CD38 antibodies, targeting T-ALL cells expressing CD38, on tumor cell killing through antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC). The study shows that IgA2 variants of CD38 antibodies are more effective in killing tumor cells through myeloid cells. The interactions between CD47 and SIRP alpha negatively regulate ADCP and ADCC. Additionally, treatment with all-trans retinoic acid (ATRA) enhances CD38 expression and further enhances ADCP and ADCC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Fotini Vogiatzi, Julia Heymann, Kristina Muller, Dorothee Winterberg, Aneta Drakul, Thies Rosner, Lennart Lenk, Michelle Heib, Carina Lynn Gehlert, Gunnar Cario, Martin Schrappe, Alexander Claviez, Beat Bornhauser, Jean-Pierre Bourquin, Simon Bomken, Dieter Adam, Fabian-Simon Frielitz, Britta Maecker-Kolhoff, Martin Stanulla, Thomas Valerius, Matthias Peipp, Christian Kellner, Denis M. Schewe
Summary: The addition of the Bcl-2 inhibitor venetoclax enhances the efficacy of therapeutic antibodies by increasing antibody-dependent cellular phagocytosis mediated by macrophages.
Article
Immunology
Katja Klausz, Lukas Pekar, Ammelie Svea Boje, Carina Lynn Gehlert, Steffen Krohn, Tushar Gupta, Yanping Xiao, Simon Krah, Rinat Zaynagetdinov, Britta Lipinski, Lars Toleikis, Sven Poetzsch, Brian Rabinovich, Matthias Peipp, Stefan Zielonka
Summary: By generating novel NKCEs, it is possible to effectively induce NK cell-mediated tumor cell lysis and release proinflammatory cytokines, which may have significant implications for anti-tumor therapy.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Immunology
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Roesner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp
Summary: This study engineered a CD19 antibody to enhance effector cell-mediated killing and CDC activity. The dual optimized CD19 antibody showed improved ADCC, ADCP, and CDC compared to the non-engineered antibody. This finding is crucial for improving CD19-directed cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Tobias Zeller, Sebastian Lutz, Ira A. Muennich, Roland Windisch, Patricia Hilger, Tobias Herold, Natyra Tahiri, Jan C. Banck, Oliver Weigert, Andreas Moosmann, Michael Von Bergwelt-Baildon, Cindy Flamann, Heiko Bruns, Christian Wichmann, Niklas Baumann, Thomas Valerius, Denis M. Schewe, Matthias Peipp, Thies Roesner, Andreas Humpe, Christian Kellner
Summary: Blocking both CD47 and LILRB1 can enhance the phagocytosis of lymphoma cells by macrophages, improving the efficacy of antibody therapy for chronic lymphocytic leukemia and lymphomas.
FRONTIERS IN IMMUNOLOGY
(2022)
Editorial Material
Immunology
Peter Boross, Matthias Peipp, Falk Nimmerjahn
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Britta Lipinski, Paul Arras, Lukas Pekar, Daniel Klewinghaus, Ammelie Svea Boje, Simon Krah, Jasmin Zimmermann, Katja Klausz, Matthias Peipp, Vanessa Siegmund, Andreas Evers, Stefan Zielonka
Summary: In this study, potent NK cell engagers (NKCEs) targeting NKp46 and EGFR were developed using single domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of Cetuximab. Various VHH domains were obtained by immunization of camelids and yeast surface display. The resulting Fc effector-silenced NKCEs showed picomolar range potency in NK cell-mediated killing of EGFR-overexpressing tumor cells, which was further enhanced by co-engagement of Fc gamma receptor IIIa (Fc gamma RIIIa). The NKp46-specific sdAbs allowed the construction of different NKCE formats with favorable biophysical and biochemical properties, leading to significantly improved killing capacities.